近畿大学ライフサイエンス研究所Kindai University Life Science Research Institute

平成23年度

巻頭言

平成23年度
ライフサイエンス研究所紀要発刊によせて
前研究所長（平成26年10月1日の人事異動により）
楠　進（医学部内科学教室神経内科学部門教授、前医学部長）

　ライフサイエンス研究所は近畿大学本部直轄の組織で、医学部からは独立した研究施設ですが、医学部の建物内にあり、機器備品およびほとんどの教員、技術員が医学部共同研究施設と共有、共同兼任の状態にあることから、医学部の研究にも寄与するところの大きな施設といえるでしょう。
　私立大学医学部や私立医科大学で基礎的な研究に専念する医学部出身者は元来多くありませんでしたが、新臨床研修医制度の導入で母校の医学部に残る卒業生自体が減少し、研究を志向する若い医師は非常に少なくなってきました。私どものライフサイエンス研究所も研究者不足、若い医師の研究志向の低下の影響をうけていると考えられます。
　しかし、時間も研究費も潤沢とはいえない中で、多くの質の高い研究成果が発表されたことは、誠に喜ばしいことと考えます。基礎系および臨床系の多くの教室の多大な御尽力と、研究所の技術員の奮闘に敬意を表するとともに、引き続いての御協力をお願いする次第です。

平成23年度ライフサイエンス研究所紀要

公衆衛生学教室（伊木　雅之　教授）

  1. Serum undercarboxylated osteocalcin levels are inversely associated with glycemic status and insulin resistance in an elderly Japanese male population: Fujiwara-kyo Osteoporosis Risk in Men (FORMEN) Study. Iki M, Tamaki J, Fujita Y, Kouda K, Yura A, Kadowaki E, Sato Y, Moon JS, Tomioka K, Okamoto N, Kurumatani N. Osteoporos Int. 2012 Feb;23(2):761-70.
  2. Association between vitamin K intake from fermented soybeans, natto, and bone mineral density in elderly Japanese men: the Fujiwara-kyo Osteoporosis Risk in Men (FORMEN) study. Fujita Y, Iki M, Tamaki J, Kouda K, Yura A, Kadowaki E, Sato Y, Moon JS, Tomioka K, Okamoto N, Kurumatani N. Osteoporos Int. 2012 Feb;23(2):705-14.
  3. Alcohol intake and bone status in elderly Japanese men: baseline data from the Fujiwara-kyo osteoporosis risk in men (FORMEN) study. Kouda K, Iki M, Fujita Y, Tamaki J, Yura A, Kadowaki E, Sato Y, Moon JS, Morikawa M, Tomioka K, Okamoto N, Kurumatani N. Bone. 2011 Aug;49(2):275-80.

細菌学教室（義江　修　教授）

  1. 「ケモカイン/ケモカインレセプターの生理機能と病的役割に関する研究」
    1. CCR4発現を誘導する転写因子FRA-2の皮膚T細胞リンパ腫における異所性発現と発がんとの関係
    2. CCR4陽性成熟型T細胞腫瘍におけるFRA-2-SOX4発癌遺伝子カスケードの役割
    3. HTLV-1潜伏感染期で発現するc-MafによるTax抑制機構の解析
    4. CCL26/eotaxin-3によるCX3CR1陽性細胞傷害性T細胞の新規遊走作用
    医学部細菌学教室（主任：義江　修　教授）
    中山　隆志、樋口　智紀、稗島　州雄、重田　暁子、義江　修

ゲノム生物学教室（西尾　和人　教授）

  1. A Novel Mass Spectrometry–Based Assay for Diagnosis of EML4-ALK–Positive Non–Small Cell Sakai, K, Okamoto I, Takezawa K, Hirashima T, Kaneda H, Takeda M, Matsumoto K, Kimura H, Fujita Y, Nakagawa K, Arao T, Nishio K. Lung Cancer. J Thor Oncol [Epub ahead of print].
  2. Clinical outcome for EML4-ALK-positive patients with advanced non-small-cell lung cancer treated with first-line platinum-based chemotherapy. Takeda M1, Okamoto I, Sakai K, Kawakami H, Nishio K, Nakagawa K. Ann Oncol. 2012 Nov;23(11):2931-6.
  3. An in vivo highly antitumor-active tetrazolato-bridged dinuclear platinum(ii) complex largely circumvents in vitro cisplatin resistance: two linkage isomers yield the same product upon reaction with 9-ethylguanine but exhibit different cytotoxic profiles. Uemura M, Suzuki T, Nishio K, Chikuma M, Komeda S. Metallomics. [Epub ahead of print]
  4. Epidermal growth factor receptor mutation status in circulating free DNA in serum: from IPASS, a phase III study of gefitinib or carboplatin/paclitaxel in non-small cell lung cancer. Goto, K., Ichinose, Y., Ohe, Y., Yamamoto, N., Negoro, S., Nishio, K., Itoh, Y., Jiang, H., Duffield, E., McCormack, R., Saijo, N., Mok, T., Fukuoka, M. J Thorac Oncol 7(1), 115-21, 2012.
  5. Marked response to both S-1 and pemetrexed in a patient with echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase-positive lung adenocarcinoma. Kaneda, H., Okamoto, I., Sakai, K., Tanizaki, J., Takeda, M., Nishio, K., Nakagawa, K. Acta Oncol, [Epub ahead of print]
  6. FGFR2 gene amplification and clinicopathological featuers in gastric cancer. Matsumoto, K., Arao, T., Hamaguchi, T., Shimada, Y., Kato, K., Oda, I., Taniguchi, H., Koizumi, F., Yanagihara, K., Sasaki, H., Nishio, K., Yamada, Y. Br J Cancer 106(4),727-32 ,2012
  7. Combined effect of ALK and MEK inhibotors in EML4-ALK-positive non-small-cell lung cancer cells. Tanizaki, J., Okamoto, I., Takezawa, K., Sakai, K., Azuma, K., Kuwata, K., Yamaguchi, H., Hatashita, E., Nishio, K., Janne, PA., Nakagawa, K. Br J Cancer 106(4), 763-7, 2012
  8. Expression changes in arrestin β1 and genetic variation in catechol-O-methyltransferase are biomarkers for the response to morphine treatment in cancer patients. Matsuoka, H., Arao, T., Makimura, C., Takeda, M., Kiyota, H., Tsurutani, J., Fujita, Y., Matsumoto, K., Kimura, H., Otsuka, M., Koyama, A., Imamura, CK., Tanigawara, Y., Yamanaka, T., Tanaka, K., Nishio, K., Nakagawa, K. Oncol Rep 27(5), 1393-9, 2012
  9. Plasma concentrations of angiogenesis-related molecules in patients with pancreatic cancer. Sakamoto, H., Kimura, H., Sekijima, M., Matsumoto, K., Arao, T., Chikugo, T., Yamada, Y., Kitano, M., Ito, A., Takeyama, Y., Kudo, M., Nishio, K. Jpn J Clin Oncol 42(2), 105-12, 2012
  10. What can and cannnot be done using a microarray analysis? Treatment stratification and clinical applications in oncology. Arao, T., Matsumoto, K., Megawa, M., Nishio, K. Biol Pharm Bull 34(12), 1789-93, 2011
  11. Serum heparan sulfate concertration is correlated with the failure of epidermal growth factor receptor tyrosine kinase inhibitor treatment in patients with lung adenocarcinoma. Nishio, M., Yamanaka, T., Matsumoto, K., Kimura, H., Sakai, K., Sakai, A., Sone, T., Horiike, A., Koizumi, F., Kasahara, K., Ohira, T., Ikeda, N., Saijo, N., Arao, T., Nishio, K. J Thorac Oncol 6(11),1889-94, 2011
  12. EGRI and FOSB gene expressions in cancer stroma are independent prognostic indicators for epithelial ovarian cancer receiving standard therapy. Kataoka F, Tsuda H, Arao T, Nishimura S, Tanaka H, Nomura H, Chiyoda T, Hirasawa A, Akahane T, Nishio H, Nishio K, Aoki D. Genes Chromosomes Cancer. 51(3):300-12, 2012.
  13. SRPX2 is a novel chondroitin sulfate proteoglycan that is overexpressed in fastrointestinal cancer. Tanaka, K., Arao, T., Tamura, D., Aomatsu, K., Furuta, K., Matsumoto, K., Kaneda, H., Kudo, K., Fujita, Y., Kimura, H., Yanagihara, K., Yamada, Y., Okamoto, I., Nakagawa, K., Nishio, K. Plos One 7(1), e27922, 2012
  14. Integrated analysis of whole genome exon array and array-comparative genomic hybridization in gastric and colorectal cancer cells. Furuta, K., Arao, T., Sakai, K., Kimura, H., Nagai, T., Tamura, D., Aomatsu, K., Kudo, K., Kaneda, H., Fujita, Y., Matsumoto, K., Yamada, Y., Yanagihara, K., Sekijima, M., Nishio, K. Cancer Sci, 103(2), 221-7, 2012
  15. Successful long-term treatment with pemetrexed of NSCLC associated with EML4-ALK and low thymidylate synthase expression. Takeda, M., Okamoto, I., Sakai, K., Tanaka, K., Terashima, M., Nishio, K., Nakagawa, K. Clin Lang Cancer 13(2), 157-9, 2012
  16. Activation of ERBB2 signaling causes resistance to the EGFR-derected therapeutic antibody cetuximab. Yonesaka, K., Zejmullahu, K., Okamoto, I., Satoh, T., Cappuzzo, F., Souglakos, J., Ercan, D., Rogers, A., Roncalli, M., Takeda, M., Fujisaka, Y., Philips, J., Shimizu, T., Maenishi, O, Cho, Y., Sun, J., Destro, A., Taira, K., Takeda, K., Okabe, T., Swanson, J., Shivdasani, RA., Nishio, K., Fukuoka, M., Verella-Garcia, M., Nakagawa, K., Janne, PA. Sci Transl Med 3(99), 99ra86, 2011
  17. Phase I study of continuous afativib (BIBW2992) in patients with advanced non-small cell lung cancer after prior chemotherapy/erlotinib/gefitinib (LUX-Lung 4). Murakami, H., Tamura, T., Takahashi, T., Nokihara, H., Naito, T., Nakamura, Y., Nishio, K., Seki, Y., Sarashina, A., Shahidi, M., Yamamoto, N. Cancer Chemother Pharmacol 69(4), 891-9, 2012
  18. Aza-derivatives of resveratrol are potent macrophage migration inhibitory factor inhibitors. Fujita, Y., Islam, R., Kaneda, H., Kudo, K., Tamura, D., Aomatsu, K., Nagai, T., Kimura, H., Matsutmoto, K., Velasco, MA., Arao, T., Okawara, T., Nishio, K. Invest New Drugs[Epub ahead of print]
  19. Activin a inhibits vascular endothelial cell growth and suppresses tumor angiogensis in gastric cancer. Kaneda, H., Arao, T., Matsumoto, K., Velasc, MA., Tamura, D., Aomatsu, K., Kudo, M., Sakai, K., Nagai, T., Fujita, Y., Tanaka, K., Yanagihara, K., Yamada, Y., Okamoto, I., Nakagawa, K., Nishio, K. Br J Cancer 105(8), 1210-7 2011
  20. Prospective study evaluating the plasma concentrations of twenty-six cytokines and response to morphine treatment in cancer patients. Makimura, C., Arao, T., Matsumoto, K., Takeda, M., Kiyota, H., Tsurutani, J., Fujita, Y., Matsumoto, K., Kimura, H., Otsuka, M., Koyama, A., Imamura, CK., Yamanaka, T., Nishio, K., Nakagawa, K. Anticancer Res 31(12), 4561-8, 2011
  21. What can and cannot be done using a microarray analysis? Treatment stratification and clinical applications in oncology. Arao T, Matsumoto K, Maegawa M, Nishio K. Biol Pharm Bull. 2011;34(12):1789-93.
  22. Acquired Drug Resistance to Vascular Endothelial Growth Factor Receptor 2 Tyrosine Kinase Inhihitor in Human Vascular Endothelial Cells. TOKUZO ARAO, KAZUKO MATSUMOTO, KAZUYUKI FURUTA, KANAE KUDO, HIROYASU KANEDA, TOMOYUKI NAGAI, KAZUKO SAKAI, YOSHIHIKO FUJITA, DAISUKE TAMURA, KEIKCHI AOMATSU, FUMIAKI KOIZUMI, and KAZUTO NISHIO.
  23. Sunitinib inhibits lymphatic endothelial cell functions and lymph node metastasis in a breast cancer model through inhibition of vascular endothelial growth factor receptor 3. Kodera, Y., Katanasaka, Y., Kitamura, Y., Hitoshi, T., Nishio, K., Tamura, T., Koizumi, F. Breast Cancer Res. 13(3), R66, 2011
  24. Differential roles of STAT3 depending on the mechanism of STAT3 activation in gastric cancer cells. Okamoto, W., Okamoto, I., Arao, T., Yanagihara, K., Nishio, K., Nakagawa, K. Br J Cancer 105(3) 407-12, 2011.
  25. Phase I dose escalation study and biomarker analysis of E7080 in patients with advanced solid tumors. Yamada, K., Yamamoto, N., Yamada, Y., Nohihara, H., Fujiwara, Y., Hirata, T., Koizumi, F., Nishio, K., Koyama, N., Tamura, T. Clin Cancer Res 17(8), 2528-37 2011
  26. Switching addictions between HER2 and FGFR2 in HER2-positive breast tumor cells: FGFR2 as a potential target for salvage after lapatinib failure. Azuma, K., Tsurutani, J., Sakai, K., Kaneda, H., Fujisaka, Y., Takeda, M., Watatani, M., Arao, T., Satoh T., Okamoto, I., Kurata, T., Nishio, K., Nakagawa, K. Biochem Biophys Res Commun 407(1) 219-24, 2011
  27. TGF-β induces sustained up-regulation of SNAI1 and SNAI2 through Smad and non-Smad pathways in a human corneal epithelial cell line. Aomatsu, K., Arao, T., Sugioka, K., Matsumoto, K., Tamura, D., Kudo, K., Kaneda, H., Tanaka, K., Fujita, Y., Shimomura, Y., Nishio, K. Invest Ophthalmol Vis Sci 52(5), 2437-43, 2011
  28. Thymidylate synthase as a determinant of permetrexed sensitivity in non-snall cell lung cancer. Takezawa, K., Okamoto, I., Okamoto, W., Takeda, M., Sakai, K., Tsukioka, S., Kuwata, K., Yamaguchi, H., Nishio, K., Nakagawa, K. Br J Cancer 104(10), 159-601, 2011
  29. Role of ERK-BIM and STAT3-Suryivin Signaling Pathways in ALK Inhibitor-Induced Apoptosis in EML4-ALK-Positive Lung Cancer. Ken Takezawa, Isamu Okamoto, Kazuto Nishio, Pasi A, Janne, and Kazuhiko Nakagawa.
  30. Roles of BIM induction and survivin downregulation in lapatinib-induced apoptosis in breast cancer cells with HER2 amplification. Tanizaki, J., Okamoto, I., Fumita, S., Okamoto, W., Nishio, K., Nakagawa, K. Oncogene, 30(39), 4097-106, 2011
  31. Sorafenib inhibits the hepatocyte growth factor-mediated epithelial mesenchymal transition in hepatocellular carcinoma. Nagai, T., Arao, T., Furuta, K., Sakai, K., Kudo, K., Kaneda, H., Tamura, D., Aomatsu, K., Kimura, H., Fujita, Y., Matsumoto, K., Saijo, N., Kudo, M., Nishio, K. Mol Cancer Ther 10(1) ,169-77, 2011
    32. 6
  32. Slug is upregulated during wound healing and regulates cellular phenotypes in corneal epithelial cells. Aomatsu, K., Arao, T., Abe, K., Kodama, A., Sugioka, K., Matsumoto, K., Kudo, K., Kimura, H., Fujita, Y., Hayashi, H., Nagai, T., Shimomura, Y., Nishio, K. Invest Ophthalmol Vis Sci. 53(2), 751-6 , 2012
  33. Developments for a growing Japanese patient population: Fcilitating new technologies for future health care. Kato, G., Nishimura, T., Ikeda, N., Yamada, T., Kondo, T., Saijo, N., Nishio, K., Fujimoto, J., Nomura, M., Oda, Y., Lindmark, B., Maniwa, J., Hibino, H., Unno, M., Ito, T., Sawa, Y., Tojo, H., Egawa, S., Edula, G., Lopez, M., Wigmore, M., Inase, N., Yoshizawa, Y., Nomura, F., Marko-Varga, G. J Proteomics 74(6), 759-64, 2011
  34. Antitumor activity of BIBF 1120, a Triple Angiokinase Inhibitor, and Use of VEGFR2+pTyr+ Peripheral Blood Leukocytes as a Pharmacodynamic Biomarker. Kudo, K., Arao, T., Tanaka, K., Nagai, T., Furuta, K., Sakai, K., Kaneda, H., Matsumoto, K., Tamura, D., Aomatsu, K., Marco DA., Fujita, Y., Saijo, N., Kudo, M., Nishio, K. Clin Cancer Res 17(6),1373-81, 2011.3
  35. Three-gene predictor of clinical outcome for gastric cancer patients treated with chemotherapy. Kim, HK., Choi, IJ., Kim, CG., Kim, HS., Oshima, A., Yamada, Y., Arao, T., Nishio, K., Michalowski, A., Green, JE. The Pharmacogenomics J 12(2), 119-27, 2012
  36. Enhanced expression of nuclear factor I/B in oxaliplatin-resistant human cancer cell lines. Kashiwagi, E., Izumi, H., Yasuniwa, Y., Baba, R., Doi, Y., Kidani, A., Arao, T., Nishio, K., Naito, S., Kohno, K. Cancer Sci 102(2), 382-6, 2011
  37. FcγR 2A and 3A polymorphisms predict clinical outcome of trastuzumab in both neoadjuvant and metastatic settings in patients with HER2 positive breast cancer. Tamura, K., Shimizu, C., Hojo, T., Akashi-Tanaka, S., Kinoshita, T., Yonemori, K., Kouno, T., Katsumata, N., Ando, M., Aogi, K., Koizumi, F., Nishio, K., Fujiwara, Y. Ann Oncol 22(6), 1302-7,2011
  38. The cancer stem cell marker CD133 is a predictor of the effectiveness of S1+ pegylated interferon alpha-2b therapy against advanced hepatocellular carcinoma. Hagiwara, S., Kudo, M., Ueshima, K., Chung, H., Yamaguchi, M., Takita, M., Haji, S,, Kimura, M., Arao, T., Nishio, K., Park, AM., Munakata, H. J. Gastroenterol46(2), 212-21, 2011

archive

近畿大学
近畿大学医学部

Copyright (C) Kindai University Life Science Research Institute All rights reserved.